Fig. 1

Study design. ^aDiscontinuation was defined as a ≥ 45-day gap (following a 30-day supply dispensing) or a ≥ 105-day gap (following a 90-day supply dispensing) in the days’ supply of cariprazine. ^bOutcomes were evaluated over the full on-treatment period (truncated at 12 months) and when censored at 3 and 6 months on treatment. ^cContinuous clinical activity was defined as consecutive quarters with ≥ 1 pharmacy, medical, or hospital claim. AA: atypical antipsychotic; BMI: body mass index; LAI: long-acting injectable